BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 15017504)

  • 41. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
    Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease].
    Nos P; Hinojosa J; Aguilera V; Molés JR; Pastor M; Ponce J; Berenguer J
    Gastroenterol Hepatol; 2000 Oct; 23(8):374-8. PubMed ID: 11227650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticosteroid-sparing treatments in patients with Crohn's disease.
    Plevy SE
    Am J Gastroenterol; 2002 Jul; 97(7):1607-17. PubMed ID: 12135008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
    Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
    Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease.
    Tillinger W; Gasche C; Reinisch W; Lichtenberger C; Bakos S; Dejaco C; Moser G; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1998 Oct; 93(10):1848-53. PubMed ID: 9772043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
    Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.
    Bossa F; Latiano A; Rossi L; Magnani M; Palmieri O; Dallapiccola B; Serafini S; Damonte G; De Santo E; Andriulli A; Annese V
    Am J Gastroenterol; 2008 Oct; 103(10):2509-16. PubMed ID: 18721243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
    Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of budesonide and mesalamine for active Crohn's disease.
    Lowry PW; Sandborn WJ
    Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
    [No Abstract]   [Full Text] [Related]  

  • 56. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE; Hanauer SB
    Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
    Hartmann F; Stein J;
    Aliment Pharmacol Ther; 2010 Aug; 32(3):368-76. PubMed ID: 20491741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide.
    Miehlke S; Madisch A; Voss C; Morgner A; Heymer P; Kuhlisch E; Bethke B; Stolte M
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1115-9. PubMed ID: 16305725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M; Mary JY; Duclos B; Veyrac M; Dupas JL; Delchier JC; Laharie D; Moreau J; Cadiot G; Picon L; Bourreille A; Sobahni I; Colombel JF;
    Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.